Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.69 |
| ▸ | CA12 | O43570 | 2/20 | 0.61 |
| ▸ | CA1 | P00915 | 2/20 | 0.61 |
| ▸ | CA2 | P00918 | 2/20 | 0.61 |
| ▸ | CA7 | P43166 | 2/20 | 0.61 |
| ▸ | CA9 | Q16790 | 2/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.61 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.61 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | MYC | P01106 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23226553 | 0.87 | CFTR (0.57) | CFTRCA12CA1CA2CA7 | |
| SCHEMBL23231573 | 0.87 | CFTR (0.53) | CFTRCA12CA1CA2CA7 | |
| SCHEMBL13280707 | 0.86 | CFTR (0.64) | CFTRCA12CA1CA2CA7 | |
| SCHEMBL22263091 | 0.86 | CFTR (0.73) | CFTRCA12CA1CA2CA7 | |
| SCHEMBL3263823 | 0.85 | GAA (0.60) | CFTRCA12CA1CA2CA7 | |
| SCHEMBL9503911 | 0.85 | CA12 (0.55) | CFTRCA12CA1CA2CA7 | |
| SCHEMBL167426 | 0.84 | CFTR (0.71) | CFTRCA12CA1CA2CA7 | |
| SCHEMBL3157053 | 0.84 | CA12 (0.62) | CFTRCA12CA1CA2CA7 | |
| SCHEMBL3590930 | 0.83 | CFTR (0.49) | CFTRCA12CA1CA2CA7 | |
| SCHEMBL2002005 | 0.83 | CFTR (0.69) | CFTRCA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382296-A1 | NITROGEN-CONTAINING FUSED THREE RING PRMT5 INHIBITOR, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | ABBISKO THERAPEUTICS CO LTD (CN) | 2025-12-18 | — | — | US | disclosed |
| US-20250320202-A1 | PRMT5 INHIBITOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | ABBISKO THERAPEUTICS CO LTD (CN) | 2025-10-16 | — | — | US | disclosed |
| EP-4567036-A1 | NITROGEN-CONTAINING FUSED THREE RING PRMT5 INHIBITOR, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2025-06-11 | — | — | EP | disclosed |
| EP-4556473-A1 | PRMT5 INHIBITOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2025-05-21 | — | — | EP | disclosed |
| WO-2024027370-A1 | NITROGEN-CONTAINING FUSED THREE RING PRMT5 INHIBITOR, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 上海和誉生物医药科技有限公司 | 2024-02-08 | — | — | WO | disclosed |
| WO-2024012308-A1 | PRMT5 INHIBITOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | 上海和誉生物医药科技有限公司 | 2024-01-18 | — | — | WO | disclosed |
| EP-3580224-B1 | ASK1 INHIBITING AGENTS | BIOGEN MA INC (US) | 2022-07-13 | — | — | EP | disclosed |
| EP-4001336-A1 | POLYURETHANE, POLYURETHANE PRODUCTION METHOD, CONDUCTIVE PASTE COMPOSITION, CONDUCTIVE WIRE, AND METHOD FOR PRODUCING CONDUCTIVE WIRE | Shin-Etsu Chemical Co., Ltd. (JP) | 2022-05-25 | — | — | EP | disclosed |
| US-20220157484-A1 | POLYURETHANE, POLYURETHANE PRODUCTION METHOD, CONDUCTIVE PASTE COMPOSITION, CONDUCTIVE WIRE, AND METHOD FOR PRODUCING CONDUCTIVE WIRE | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2022-05-19 | — | — | US | disclosed |
| US-11168095-B2 | ASK1 inhibiting agents | BIOGEN MA INC. (US) | 2021-11-09 | — | — | US | disclosed |
| EP-1945613-A1 | NOVEL 1 -BENZYL-4-PIPERIDINAMINES THAT ARE USEFUL IN THE TREATMENT OF COPD AND ASTHMA | AstraZeneca AB (SE) | 2008-07-23 | — | — | EP | disclosed |
| CN-101228131-A | Novel heterocyclylideneacetamide derivatives | MOCHIDA PHARM CO LTD (JP) | 2008-07-23 | — | — | CN | disclosed |
| WO-2008055068-A2 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008055068-A2 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2008-05-08 | — | — | WO | disclosed |
| EP-1908753-A1 | NOVEL HETEROCYCLIDENE ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2008-04-09 | — | — | EP | disclosed |
| EP-1861092-A1 | POTASSIUM CHANNEL OPENER HAVING BENZOFUROINDOLE SKELETON | Anygen Co., Ltd. (KR) | 2007-12-05 | — | — | EP | disclosed |
| WO-2007053082-A1 | NOVEL 1 -BENZYL-4-PIPERIDINAMINES THAT ARE USEFUL IN THE TREATMENT OF COPD AND ASTHMA | ASTRAZENECA AB (SE) | 2007-05-10 | — | — | WO | disclosed |
| WO-2006096030-A1 | POTASSIUM CHANNEL OPENER HAVING BENZOFUROINDOLE SKELETON | ANYGEN CO., LTD. (KR) | 2006-09-14 | — | — | WO | disclosed |
| EP-0711286-A1 | BENZOXAZINONES AND BENZOTHIAZINONES ENDOWED WITH THERAPEUTIC ACTIVITY | ITALFARMACO S.p.A. (IT) | 1996-05-15 | — | — | EP | disclosed |
| WO-1995004048-A1 | BENZOXAZINONES AND BENZOTHIAZINONES ENDOWED WITH THERAPEUTIC ACTIVITY | ITALFARMACO S.P.A. (IT) | 1995-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382296-A1 | NITROGEN-CONTAINING FUSED THREE RING PRMT5 INHIBITOR, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | PRMT5, PRMT1, PRMT8 | CFTR 3765/4885CA12 4778/4885CA1 4480/4885 |
| US-11168095-B2 | ASK1 inhibiting agents | MAP3K1, MAP3K10, MAP3K20 | CFTR 1921/4885CA12 4819/4885CA1 3842/4885 |
| US-20250320202-A1 | PRMT5 INHIBITOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | PRMT5, PRMT1, PRMT8 | CFTR 3484/4885CA12 4821/4885CA1 4595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.